259
Participants
Start Date
April 20, 2017
Primary Completion Date
August 31, 2021
Study Completion Date
August 31, 2021
Discontinuation of disease modifying therapy
Participants who will discontinue their current MS drug. No other changes to their treatment occur.
Standard of Care
Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
NYU Langone Medical Center, New York
Mt. Sinai University, New York
University of Rochester, Rochester
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Georgetown University, Washington D.C.
University of Virginia, Charlottesville
University of Miami, Miami
Vanderbilt University, Nashville
The Ohio State University, Columbus
Cleveland Clinic, Cleveland
Washington University St. Louis, St Louis
University of Kansas Medical Center, Kansas City
University of Colorado Denver - Anschutz Medical Campus, Aurora
University of Southern California, Los Angeles
Oregon Health and Science University, Portland
Swedish Health Services, Seattle
Massachusetts General Hospital, Boston
Patient-Centered Outcomes Research Institute
OTHER
National Multiple Sclerosis Society
OTHER
University of Alabama at Birmingham
OTHER
University of Colorado, Denver
OTHER